285 related articles for article (PubMed ID: 33321758)
1. Liposomes Targeting P21 Activated Kinase-1 (PAK-1) and Selective for Secretory Phospholipase A
Najahi-Missaoui W; Quach ND; Somanath PR; Cummings BS
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33321758
[TBL] [Abstract][Full Text] [Related]
2. Effect of P21-activated kinase 1 (PAK-1) inhibition on cancer cell growth, migration, and invasion.
Najahi-Missaoui W; Quach ND; Jenkins A; Dabke I; Somanath PR; Cummings BS
Pharmacol Res Perspect; 2019 Oct; 7(5):e00518. PubMed ID: 31516713
[TBL] [Abstract][Full Text] [Related]
3. Evidence for distinct mechanisms of uptake and antitumor activity of secretory phospholipase A2 responsive liposome in prostate cancer.
Mock JN; Costyn LJ; Wilding SL; Arnold RD; Cummings BS
Integr Biol (Camb); 2013 Jan; 5(1):172-82. PubMed ID: 22890797
[TBL] [Abstract][Full Text] [Related]
4. Liposome-mediated delivery of the p21 activated kinase-1 (PAK-1) inhibitor IPA-3 limits prostate tumor growth in vivo.
Al-Azayzih A; Missaoui WN; Cummings BS; Somanath PR
Nanomedicine; 2016 Jul; 12(5):1231-1239. PubMed ID: 26949163
[TBL] [Abstract][Full Text] [Related]
5. Sterically stabilized liposomes targeting P21 (RAC1) activated kinase-1 and secreted phospholipase A
Verma A; Najahi-Missaoui W; Cummings BS; Somanath PR
Oncol Lett; 2020 Nov; 20(5):179. PubMed ID: 32934746
[TBL] [Abstract][Full Text] [Related]
6. Revisiting the use of sPLA
Pourhassan H; Clergeaud G; Hansen AE; Østrem RG; Fliedner FP; Melander F; Nielsen OL; O'Sullivan CK; Kjær A; Andresen TL
J Control Release; 2017 Sep; 261():163-173. PubMed ID: 28662900
[TBL] [Abstract][Full Text] [Related]
7. Role of the phospholipase A2 receptor in liposome drug delivery in prostate cancer cells.
Quach ND; Mock JN; Scholpa NE; Eggert MW; Payré C; Lambeau G; Arnold RD; Cummings BS
Mol Pharm; 2014 Oct; 11(10):3443-51. PubMed ID: 25189995
[TBL] [Abstract][Full Text] [Related]
8. Secretory phospholipase (sPLA
Mehta D; Shaikh S; Mohanty B; Chaudhari P; Waghmare SK
Biochem Biophys Res Commun; 2023 Oct; 677():98-104. PubMed ID: 37566923
[TBL] [Abstract][Full Text] [Related]
9. Indocyanine green loaded liposome nanocarriers for photodynamic therapy using human triple negative breast cancer cells.
Shemesh CS; Hardy CW; Yu DS; Fernandez B; Zhang H
Photodiagnosis Photodyn Ther; 2014 Jun; 11(2):193-203. PubMed ID: 24657627
[TBL] [Abstract][Full Text] [Related]
10. Oleanolic acid protects against cognitive decline and neuroinflammation-mediated neurotoxicity by blocking secretory phospholipase A2 IIA-activated calcium signals.
Zhang L; Xia R; Jia J; Wang L; Li K; Li Y; Zhang J
Mol Immunol; 2018 Jul; 99():95-103. PubMed ID: 29747052
[TBL] [Abstract][Full Text] [Related]
11. Secretory phospholipase A
Østrem RG; Parhamifar L; Pourhassan H; Clergeaud G; Nielsen OL; Kjær A; Hansen AE; Andresen TL
J Control Release; 2017 Sep; 262():212-221. PubMed ID: 28754610
[TBL] [Abstract][Full Text] [Related]
12. Group I PAK inhibitor IPA-3 induces cell death and affects cell adhesivity to fibronectin in human hematopoietic cells.
Kuželová K; Grebeňová D; Holoubek A; Röselová P; Obr A
PLoS One; 2014; 9(3):e92560. PubMed ID: 24664099
[TBL] [Abstract][Full Text] [Related]
13. Induction of AMPK activation by N,N'-diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers.
Johnson J; Rychahou P; Sviripa VM; Weiss HL; Liu C; Watt DS; Evers BM
PLoS One; 2019; 14(3):e0209392. PubMed ID: 30875375
[TBL] [Abstract][Full Text] [Related]
14. Secretory phospholipase A2 mediates human esophageal adenocarcinoma cell growth and proliferation via ERK 1/2 pathway.
Sadaria MR; Yu JA; Meng X; Fullerton DA; Reece TB; Weyant MJ
Anticancer Res; 2013 Apr; 33(4):1337-42. PubMed ID: 23564770
[TBL] [Abstract][Full Text] [Related]
15. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy.
Chang CH; Bijian K; Wernic D; Su J; da Silva SD; Yu H; Qiu D; Asslan M; Alaoui-Jamali MA
Autophagy; 2019 Aug; 15(8):1376-1390. PubMed ID: 30773992
[TBL] [Abstract][Full Text] [Related]
16. β-elemene enhances the radiosensitivity of gastric cancer cells by inhibiting Pak1 activation.
Liu JS; Che XM; Chang S; Qiu GL; He SC; Fan L; Zhao W; Zhang ZL; Wang SF
World J Gastroenterol; 2015 Sep; 21(34):9945-56. PubMed ID: 26379399
[TBL] [Abstract][Full Text] [Related]
17. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
18. Lipid droplets induced by secreted phospholipase A
Jarc E; Kump A; Malavašič P; Eichmann TO; Zimmermann R; Petan T
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Mar; 1863(3):247-265. PubMed ID: 29229414
[TBL] [Abstract][Full Text] [Related]
19. Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer.
Dai W; Yang F; Ma L; Fan Y; He B; He Q; Wang X; Zhang H; Zhang Q
Biomaterials; 2014 Jul; 35(20):5347-5358. PubMed ID: 24726747
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel PAK1/HDAC6 dual inhibitor ZMF-23 that triggers tubulin-stathmin regulated cell death in triple negative breast cancer.
Zhang J; Chen X; Chen G; Wang H; Jia L; Hao Y; Yao D
Int J Biol Macromol; 2023 Nov; 251():126348. PubMed ID: 37586623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
